Jennifer Kayden Lee - 08 Nov 2023 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role
EVP, Head of North America
Signature
/s/ Hunter Smith, Attorney-in-Fact for Jennifer Lee
Issuer symbol
RYTM
Transactions as of
08 Nov 2023
Net transactions value
-$198,067
Form type
4
Filing time
13 Nov 2023, 17:44:01 UTC
Previous filing
07 Nov 2023
Next filing
16 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RYTM Common Stock Options Exercise $38,842 +5,712 +347% $6.80 7,359 08 Nov 2023 Direct
transaction RYTM Common Stock Sale $99,649 -3,479 -47% $28.64 3,880 08 Nov 2023 Direct F1, F2
transaction RYTM Common Stock Sale $65,456 -2,233 -58% $29.31 1,647 08 Nov 2023 Direct F1, F3
transaction RYTM Common Stock Options Exercise $23,378 +3,438 +209% $6.80 5,085 09 Nov 2023 Direct
transaction RYTM Common Stock Sale $47,051 -1,719 -34% $27.37 3,366 09 Nov 2023 Direct F1, F4
transaction RYTM Common Stock Sale $48,132 -1,719 -51% $28.00 1,647 09 Nov 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Stock Option (Right to Buy) Options Exercise $0 -5,712 -8.5% $0.000000 61,880 08 Nov 2023 Common Stock 5,712 $6.80 Direct F5
transaction RYTM Stock Option (Right to Buy) Options Exercise $0 -3,438 -5.6% $0.000000 58,442 09 Nov 2023 Common Stock 3,438 $6.80 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $28.04 to $29.01. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $29.04 to $29.70. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $26.86 to $27.51. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.